These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31169023)

  • 21. INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA: SIX YEARS OUTCOME.
    Ruiz-Moreno JM; Montero JA; Araiz J; Arias L; García-Layana A; Carneiro A; Figueroa MS; Silva R
    Retina; 2015 Dec; 35(12):2450-6. PubMed ID: 26049616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
    Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
    Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health- and vision-related quality of life among patients with ocular histoplasmosis or idiopathic choroidal neovascularization at enrollment in a randomized trial of submacular surgery: Submacular Surgery Trials Report No. 5.
    Submacular Surgery Trials Research Group
    Arch Ophthalmol; 2005 Jan; 123(1):78-88. PubMed ID: 15642816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
    Kung YH; Wu TT; Huang YH
    Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
    Wakabayashi T; Ikuno Y; Gomi F
    Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
    Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intravitreal ranibizumab therapy for choroidal neovascularization secondary to pathological myopia].
    Lukács R; Sándor G; Resch M; Szabó A; Barcsay G; Ecsedy M; Szepessy Z; Nagy ZZ; Papp A
    Orv Hetil; 2017 Apr; 158(15):579-586. PubMed ID: 28393596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
    Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
    Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
    Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan.
    Ohno-Matsui K; Suzaki M; Teshima R; Okami N
    Eye (Lond); 2018 Dec; 32(12):1871-1878. PubMed ID: 30158574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN ANGIOID STREAKS: Four-Year Follow-up.
    Tilleul J; Mimoun G; Querques G; Puche N; Zerbib J; Lalloum F; Srour M; Souied EH
    Retina; 2016 Mar; 36(3):483-91. PubMed ID: 26355947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
    Lai TY; Chan WM; Liu DT; Lam DS
    Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of visual prognoses between natural course of simple hemorrhage and choroidal neovascularization treated with intravitreal bevacizumab in highly myopic eyes: a 1-year follow-up.
    Goto S; Sayanagi K; Ikuno Y; Jo Y; Gomi F; Nishida K
    Retina; 2015 Mar; 35(3):429-34. PubMed ID: 25166271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.
    Lai TY; Luk FO; Lee GK; Lam DS
    Eye (Lond); 2012 Jul; 26(7):1004-11. PubMed ID: 22595908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia.
    Pastore MR; Capuano V; Bruyère E; Miere A; Corbelli E; Querques L; Tognetto D; Bandello F; Querques G; Souied EH
    Ophthalmologica; 2018; 239(2-3):133-142. PubMed ID: 29268267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. APPLICATION OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY TO ASSESS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Cheng Y; Li Y; Huang X; Qu Y
    Retina; 2019 Apr; 39(4):712-718. PubMed ID: 29256987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry.
    Willis J; Morse L; Vitale S; Parke DW; Rich WL; Lum F; Cantrell RA
    Ophthalmology; 2017 Jul; 124(7):935-943. PubMed ID: 28372860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study.
    Pasyechnikova NV; Naumenko VO; Korol AR; Zadorozhnyy OS; Kustryn TB; Henrich PB
    Ophthalmologica; 2015; 233(1):2-7. PubMed ID: 25501802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ranibizumab for myopic choroidal neovascularization.
    Ng DSC; Fung NSK; Yip FLT; Lai TYY
    Expert Opin Biol Ther; 2020 Dec; 20(12):1385-1393. PubMed ID: 33003962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.